AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND

PRESS RELEASE

AB SCIENCE TO PRESENT LATEST CLINICAL DATA ON LONG-TERM SURVIVAL ANALYSES IN AMYOTROPHIC LATERAL SCLEROSIS AT THE 2021 INTERNATIONAL SYMPOSIUM ON ALS/MND

Paris, 2 September, 2021, 6pm CET

AB Science SA (Euronext - FR0010557264 - AB) today announced that two scientific presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 2021 International Symposium on ALS/MND, which is being held virtually on 7–10 December. This is the largest medical and scientific conference dedicated to advancing science in MND/ALS and is the premier event in the ALS research calendar for discussion on the latest advances in research and clinical management.

The accepted abstracts include of one oral presentation during the platform session on Clinical Trials and Trial Design, and one ePoster presentation with accompanying prerecorded video commentary. All abstracts will be published in an open access online supplement to the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

Presentations Accepted to the 32^nd International Symposium on ALS/MND:

Oral presentation. Long-term follow-up of masitinib study AB10015 shows prolonged survival in patients that start treatment prior to severe impairment of functionality.
Presenting Author: Professor Albert Ludolph, MD, PhD (Chairman of the Department of Neurology at the University Hospital and Medical Faculty of Ulm and principal investigator of confirmatory masitinib phase 3 study AB19001)

ePoster presentation. Long-Term Survival Analysis from Masitinib Early Access Named Patient Program.
Presenting Author: Dr Jesus S Mora, MD (Director of the ALS Unit at Hospital San Rafael of Madrid and principal investigator of phase 3 masitinib study AB10015)

About amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disorder that is characterized by progressive loss of the upper and lower motor neurons at the spinal or bulbar level. The disease belongs to a group of disorders known as motor neuron diseases, which are characterized by the gradual degeneration and death of motor neurons. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die, and stop sending messages to muscles.
The prevalence of ALS in western countries is fairly uniform at 6 per 100,000 persons, corresponding to around 30,000 cases in Europe and 20,000 in the USA.
The first drug treatment for ALS, riluzole (Rilutek), was approved in 1995. In Europe, there has been no new treatment approved since riluzole.

About masitinib
Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website:
www.ab-science.com.

Forward-looking Statements - AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

Media Relations – USA

RooneyPartners
Kate Barrette
kbarrette@rooneyco.com

+1 646 432 0191

Media Relations – France

NewCap
Arthur Rouillé
arouille@newcap.fr

+33 (0)1 44 71 00 15

Attachment

• CP ALS_MND Symp 2021 ENG VF